Testis Cancer: Genes, Environment, Hormones by Alberto Ferlin & Carlo Foresta
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EDITORIAL
published: 21 October 2014
doi: 10.3389/fendo.2014.00172
Testis cancer: genes, environment, hormones
Alberto Ferlin* and Carlo Foresta
Centre for Human Reproduction Pathology, Department of Medicine, University of Padova, Padova, Italy
*Correspondence: alberto.ferlin@unipd.it
Edited by:
Claire Perks, University of Bristol, UK
Reviewed by:
Donatella Paoli, University of Rome La Sapienza, Italy
Keywords: testis cancer, genetics, germ cell tumors, KITLG
Testicular cancer (TC) is the most common cancer in males aged
20–40 years, with a worldwide incidence of 7.5 per 100,000, but the
rates vary considerably between countries and ethnic groups and
there is evidence also for an increasing incidence in last decades.
About 95% of all TCs are represented by testicular germ cell
tumors (TGCTs), which include seminoma and non-seminoma
histological types. It is generally assumed that the development
of TGCT is under endocrine control. In particular, unbalanced
androgen/estrogen levels and/or activity are believed to represent
the key events for TGCT development and progression.
Furthermore, recent evidence has suggested genetic association
of TGCT with variations in genes involved in hypothalamic–
pituitary–testicular axis and steroidogenic enzymes (1). This
recent evidence expands the current knowledge on the role of
genetic contribution in TC susceptibility, and supports the hypoth-
esis that variations in hormone metabolism genes might change
the hormonal environment implicated in testicular carcinogenesis.
Therefore, hormonal carcinogenesis is an important and contro-
versial area of current research in TGCT, and further attention is
given to genetic factors influencing hormone-related cancer risk.
The genetic component to TGCT is in general strong. In fact,
although environmental factors clearly contribute to TGCT devel-
opment (and probably to its increasing incidence in some geo-
graphical areas), the proportion of TGCT susceptibility accounted
for by the genetic effects is estimated at 25%. TGCT has high famil-
ial risks compared with most other cancer types that are generally
not more than twofold: brothers of individuals with TGCT have
an 8- to 12-fold increased risk of disease, and sons of affected indi-
viduals have a 4- to 6-fold increased risk (2). Despite this strong
familial relative risk, early results from linkage studies identified
a limited relationship with genetic factors, suggesting that TGCT
is a genetically complex trait. However, more recently, genome-
wide association studies (GWAS) have reported association of
TGCTs with new loci (such as those in KITLG, SPRY4, BAK1,
DMRT1, TERT, and ATF7IP genes). The strongest association for
TGCT susceptibility was found for SNPs in KITLG (ligand for the
membrane-bound receptor tyrosine kinase KIT) gene with a >2.5-
fold increased risk of disease per major allele, which is the highest
reported for any cancer to date (3, 4). These studies are being now
replicated (5) and attention is given to the relationship between
these genetic variations, TGCT risk, and frequently associated
anomalies of the reproductive tract, such as cryptorchidism and
infertility (6). Finally, over the past few decades, TCGT research
has focused also on external environmental causes acting mainly
as endocrine disrupters of androgen and estrogen pathways, even
during the fetal development of the testis (1). It is well known
that the testicular dysgenesis syndrome (TDS) hypothesis, pro-
posed 10 years ago, suggests that disturbed testicular development
in fetal life may result in one or more of four disorders post-
natally, named cryptorchidism, hypospadias, poor semen quality,
and TGCT (7). These four disorders are therefore considered as
one clinical entity and are linked together by epidemiological and
pathophysiological relations. The relative contribution of genet-
ics and environment in TGCT development, and the interactions
between endocrine disruptors and variations in genes involved in
hormonal carcinogenesis is therefore another interesting area of
research.
The aim of this Research Topic is to give an update on the most
controversial issues in research areas of TGCT, as well as original
contributions giving novel hypotheses and understandings on the
pathogenesis and progression of TGCT. Both clinical and basic
researches are reported and many questions are addressed. One
of these deals with analysis of anthropometric measures and risk
of TGCT (8), an obscure matter that this study clarified, show-
ing that TC is positively associated with height and negatively
associated with body mass index, indirectly suggesting that mod-
ifications in hormonal factors and food intake during childhood
and puberty might influence susceptibility to cancer. The effects
of endocrine disruptors during in utero and/or neonatal develop-
ment have been a matter of discussion and areas of uncertainty
exists. One of these is the possible epigenetic modification follow-
ing exposure to these molecules and Vega and colleagues review
this topic showing how chromatin modifications, which can affect
testicular physiology might increase susceptibility to TGCT and
the potential molecular pathways involved in these alterations in
the context of environmental exposures (9).
Not only TGCT development and progression but also
treatment outcome and risks of complications from cisplatin
chemotherapy seem to be genetically determined. This is well doc-
umented by Fung and colleagues, who showed for the first time
that a polymorphism in ARVCF gene influences TGCT outcome,
carriers of risk allele being exposed to a higher risk of refractory
TGCT after initial chemotherapy (10). Furthermore, patients who
received chemotherapy had a higher risk of developing semen HPV
infection (11), potentially exposing these subjects to HPV-related
disorders and worse fertility prognosis.
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Physiological and genetic aspects of primordial germ cells,
gonocytes, and spermatogenic stem cells transformation are also
interesting research areas. One report reviewed the current knowl-
edge on the biology of the postnatal germ cell development (12),
another one looked for possible modifications, caused by copy
number variations, in genes involved in cell migration of pri-
mordial germ cells (13), and Brokken and colleagues showed
that polymorphisms in the aryl hydrocarbon receptor repressor
gene (that modulates the effects of environmental pollutants) are
associated with progression of TGCT to invasive forms (14).
Finally, this Research Topic reports review on the associa-
tion between cryptorchidism and TGCT (15, 16), clarifying that,
regardless of age at orchidopexy, unilateral vs. bilateral forms,
or position of undescended testes, patients with history of cryp-
torchidism are at higher risk of developing TGCT (15), and sug-
gesting that changes in the spermatogonial stem cell self-renewal
and differentiation in cryptorchid testes might be an important
pathway leading to TGCT (16).
Taken together, the articles presented in this Research Topic
report comprehensive review and original articles dealing with
most recent research fields in the pathogenesis, progression, and
clinical associations of TGCT.
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